Search
+
    SEARCHED FOR:

    BIOPHARMACEUTICAL COMPANY

    Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%

    The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.

    Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch

    Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request. The details of the settlement agreement remain confidential between the companies involved.

    Biocon clears path for cancer drug launch

    Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. Other global launches are planned between 2026 and 2028, depending on regulatory approvals.

    When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%

    Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.

    Kiran Mazumdar-Shaw has a career lesson from 3 Nobel prize winners as AI forces layoffs and changes jobs across the world

    Biocon chairperson Kiran Mazumdar-Shaw shared a message on persistence from three 2023 Nobel Prize winners as AI reshapes jobs and companies rethink their workforces. Her post highlighted the importance of finding reasons to keep going despite setbacks, a message that resonates with workers facing career uncertainty, layoffs and changing skill requirements.

    Ichor Biologics seeks $80-100 million PE funding for minority stake sale

    Ichor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the specialized plasmatherapy segment. Promoters Ananda Reddy Sudini and Sujana Sudini hold significant stakes in the firm. Ichor manufactures therapeutic protein products derived from human plasma. The company's products serve various critical therapeutic areas.

    The Economic Times
    BACK TO TOP